Aranesp Oncology Label Includes Emphasis On Longer Half-Life Than Procrit 

Aranesp labeling for chemotherapy-induced anemia includes increased emphasis on the product's less frequent dosing than epoetin alfa (J&J's Procrit)

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet